Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK ALK L1196M ALK G1202R ALK D1203N |
Therapy | Lorlatinib |
Indication/Tumor Type | large cell neuroendocrine carcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK L1196M ALK G1202R ALK D1203N | large cell neuroendocrine carcinoma | predicted - resistant | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, ALK L1196M, ALK D1203N, and ALK G1202R were identified on post-progression biopsy in a patient with metastatic large cell neuroendocrine lung carcinoma harboring EML4-ALK (e20:e20), who previously achieved disease stabilization for 8 months with Lorbrena (lorlatinib) treatment (PMID: 36207130). | 36207130 |
PubMed Id | Reference Title | Details |
---|---|---|
(36207130) | Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report. | Full reference... |